Anticoagulant Regimens Given to achieve thrombus regression and reduce clinical Outcomes among patients with Non device-related intra-cardiac thrombus: a randomized Assessment Under direct oral anticoagulant and vitamin K antagonist Therapy – the ARGONAUT trial

intra-cardiac thrombus

Net clinical benefit endpoint at 6 months: composite endpoint of all-cause death, myocardial infarction, stroke, acute peripheral emboli, acute pulmonary embolism, thrombus persistence and clinically relevant bleedings (Bleeding Academic Research Consortium 2, 3 and 5).

- Secondary efficacy endpoints: o All individual components of the composite ischemic endpoint at 6 and 12 months o Systemic embolism defined by the composite of stroke, embolic myocardial infarction, peripheral artery occlusion and acute pulmonary embolism at 6 and 12 months o Cardiovascular death at 6 and 12 months o Total thrombus regression at 6 and 12 months o Thrombus recurrence at different cardiac imaging follow-up, - Secondary safety endpoints: o Clinically relevant bleedings (international Bleeding Academic Research Consortium (BARC) types 2 to 5) at 6 and 12 months o Major bleedings (BARC 3 to 5) at 6 and 12 months

No related papers found yet.

France